Palacios, Santiago ORCID: 0000-0003-2229-1200, Regidor, Pedro-Antonio ORCID: 0000-0002-9551-2847, Colli, Enrico, Skouby, Sven Olaf, Apter, Dan, Roemer, Thomas, Egarter, Christian, Nappi, Rossella E., Skrivanek, Ales, Jakimiuk, Artur J., Weyers, Steven, Acs, Nandor, Elia, David, Gemzell Danielsson, Kristina and Bitzer, Johannes (2020). Oestrogen-free oral contraception with a 4 micrograms drospirenone-only pill: new data and a review of the literature. Eur. J. Contracept. Reprod. Health Care, 25 (3). S. 221 - 228. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1473-0782

Full text not available from this repository.

Abstract

Purpose: The contraceptive pill is an effective and safe method of preventing pregnancy. The progestins used for contraception either are components of a combined hormonal contraceptive (tablets, patches or vaginal rings) or are used alone in progestin-only formulations. Progestin-only contraceptives are available as daily oral preparations, subcutaneous or intramuscular injectables (every 1-3 months), subdermal implants (every 3-5 years) and intrauterine systems (every 3-5 years). Long-acting progestins are highly effective in typical use and have a very low risk profile and few contraindications. Material and Methods: A new progestin-only, oestrogen-free contraceptive, drospirenone, in a dosage of 4 mg/day in a 24/4 regimen, has received regulatory approval in the USA and the EU. The molecule has antigonadotropic, antimineralocorticoid, antiestrogenic and antiandrogenic properties. Results: The regimen was chosen to improve the bleeding profile; maintain plasma oestradiol levels at those of the early follicular phase, to avoid hypoestrogenism; and preserve efficacy even with a missed pill, as drospirenone has a half-life of 30-34 h. Conclusions: Clinical studies have shown good efficacy, very low cardiovascular side effects and a favourable bleeding pattern, as well as maintenance of ovulation inhibition after scheduled 24 h delays in pill intake.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Palacios, SantiagoUNSPECIFIEDorcid.org/0000-0003-2229-1200UNSPECIFIED
Regidor, Pedro-AntonioUNSPECIFIEDorcid.org/0000-0002-9551-2847UNSPECIFIED
Colli, EnricoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Skouby, Sven OlafUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Apter, DanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Roemer, ThomasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Egarter, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Nappi, Rossella E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Skrivanek, AlesUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jakimiuk, Artur J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Weyers, StevenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Acs, NandorUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Elia, DavidUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gemzell Danielsson, KristinaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bitzer, JohannesUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-337388
DOI: 10.1080/13625187.2020.1743828
Journal or Publication Title: Eur. J. Contracept. Reprod. Health Care
Volume: 25
Number: 3
Page Range: S. 221 - 228
Date: 2020
Publisher: TAYLOR & FRANCIS LTD
Place of Publication: ABINGDON
ISSN: 1473-0782
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
75 MU-G; OVARIAN ACTIVITY; DESOGESTREL; PROGESTOGEN; INHIBITION; PHARMACOLOGY; BENEFITS; WEIGHTMultiple languages
Public, Environmental & Occupational Health; Obstetrics & GynecologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/33738

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item